Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday

Black Diamond Therapeutics (NASDAQ:BDTX) is projected to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $25.00 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Monday, March 16th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. On average, analysts expect Black Diamond Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Black Diamond Therapeutics Stock Up 3.3%

BDTX stock traded up $0.09 during mid-day trading on Monday, reaching $2.69. The company had a trading volume of 387,522 shares, compared to its average volume of 750,503. The stock has a market capitalization of $153.82 million, a P/E ratio of 7.26 and a beta of 3.34. Black Diamond Therapeutics has a one year low of $1.46 and a one year high of $4.94. The stock’s 50-day simple moving average is $2.46 and its two-hundred day simple moving average is $2.86.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of BDTX. Arrowstreet Capital Limited Partnership raised its position in Black Diamond Therapeutics by 549.2% in the third quarter. Arrowstreet Capital Limited Partnership now owns 896,853 shares of the company’s stock worth $3,399,000 after acquiring an additional 758,709 shares in the last quarter. Marshall Wace LLP bought a new stake in Black Diamond Therapeutics in the second quarter worth about $1,830,000. Dimensional Fund Advisors LP raised its position in Black Diamond Therapeutics by 88.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 857,015 shares of the company’s stock worth $2,083,000 after acquiring an additional 401,145 shares in the last quarter. Mackenzie Financial Corp bought a new stake in Black Diamond Therapeutics in the fourth quarter worth about $876,000. Finally, Renaissance Technologies LLC raised its position in Black Diamond Therapeutics by 58.4% in the fourth quarter. Renaissance Technologies LLC now owns 949,735 shares of the company’s stock worth $2,308,000 after acquiring an additional 350,335 shares in the last quarter. 95.47% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. BTIG Research lifted their price objective on shares of Black Diamond Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. HC Wainwright restated a “buy” rating on shares of Black Diamond Therapeutics in a research note on Wednesday, April 29th. Jefferies Financial Group upgraded shares of Black Diamond Therapeutics to a “strong-buy” rating in a research note on Thursday, April 23rd. Piper Sandler cut their price objective on shares of Black Diamond Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Friday, January 16th. Finally, Weiss Ratings upgraded shares of Black Diamond Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.